The aim of the study was to evaluate diagnostic performance (sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV)) of 18F-PSMA-1007 PET/CT and compare it with 18F-FCH PET/CT in prostate cancer (PCa) patients after radical treatment and low but rising prostate-specific antigen (PSA) levels.
Methods and materials
We prospectively enrolled 40 patients after radical treatment of PCa (radical prostatectomy or radiotherapy) and low (0.008 to ≤2.0 ng/ml), rising PSA levels. 18F-FCH and 18F-PSMA-1007 PET/CT imaging was performed within a mean interval of 54±21 days. Scans were done 87±10 min and 95±12 min after injecting 248±35 MBq and 295±14 MBq of 18F-FCH and 18F-PSMA-1007, respectively. Rate of negative, equivocal and positive scan results was compared per patient. Per lesion, findings were grouped as equivocal or highly suspicious for malignancy and then compared for...
Positive, equivocal and negative results were reported in 60%, 27.5% and 12.5% of 18F-PSMA-1007 and in 5%, 37.5% and 57.5% of 18F-FCH scans, respectively. In 70% of scans, 18F-PSMA-1007 PET/CT upgraded 18F-FCH PET/CT results. 18F-PSMA-1007 scans also showed significantly more lesions (184 vs 63, p=0.0006). Local relapse, lymph node and bone lesions accounted respectively for 9%, 58% and 33% of 18F-PSMA-1007 and 5%, 89% and 6% 18F-FCH of PET/CT findings. Highly suspicious lesions accounted for 74% of 18F-PSMA-1007 and 11% of 18F-FCH PET/CT findings. In...
18F-PSMA-1007 showed a higher detection rate than 18F-FCH PET/CT. It also showed more lesions, more highly suspicious lesions and less equivocal lesions. 18F-PSMA-1007 PET/CT detection rate correlated with PSA levels. Like other PSMA-targeting radiotracers, its detection rate was dependent on PSA levels. 18FPSMA-1007 also presented excellent sensitivity, specificity and NPV.
Personal information and conflict of interest
E. Witkowska-Patena; Warsaw, MAZOWIECKIE/PL - nothing to disclose A. Giżewska; Warsaw/PL - nothing to disclose M. Dziuk; Warsaw/PL - nothing to disclose J. Misko; Warsaw/PL - nothing to disclose A. Budzynska; Warsaw/PL - nothing to disclose A. Walęcka-Mazur; Warsaw/PL - nothing to disclose N. Papachristodoulou; Budapest/HU - nothing to disclose
1. McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press. Adv Nutr. 2016;7:418–419.
2. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65:124–137.
3. Ceci F, Uprimny C, Nilica B, et al. 68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl ;Med Mol Imaging. 2015;42:1284–1294.
4. Heidenreich A,...